The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
Feature|Articles|April 1, 2026
The Rise of Early-Onset Cancers: Investigating Breast and CRC Occurrences
Author(s)Ariana Pelosci, Tim Cortese
Fact checked by: Roman Fabbricatore
The incidence rates of breast cancer and colorectal cancer have been on the rise in patients under 50 years for the past several years.
Advertisement
Advertisement
The American Cancer Society’s annual cancer statistics report highlighted that, in 2025, 2,041,910 new cancer cases and 618,120 cancer deaths were projected to occur.1 Though there is a single name for the disease—cancer—there are hundreds of subtypes. Among them, 2 of the most common are breast and colorectal cancer (CRC), and unfortunately, they are on the rise in patients younger than 50.
Related to this article
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
Advertisement
Advertisement